RxSight (RXST, Financial) has received a notable analyst upgrade from Wells Fargo, highlighting positive momentum for the company. Analyst Larry Biegelsen has raised the stock's rating from "Equal-Weight" to "Overweight," indicating a more favorable outlook.
Alongside the rating upgrade, Wells Fargo has significantly increased the price target for RXST. The new price target has been set at $25.00, up from the previous target of $17.00. This adjustment reflects a substantial price target percentage change of 47.06%.
The upgrade and increased price target from Wells Fargo come as an encouraging development for investors and stakeholders of RxSight (RXST, Financial), suggesting potential growth prospects for the stock in the upcoming periods.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for RxSight Inc (RXST, Financial) is $21.60 with a high estimate of $28.00 and a low estimate of $16.00. The average target implies an upside of 52.22% from the current price of $14.19. More detailed estimate data can be found on the RxSight Inc (RXST) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, RxSight Inc's (RXST, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for RxSight Inc (RXST, Financial) in one year is $56.98, suggesting a upside of 301.55% from the current price of $14.19. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the RxSight Inc (RXST) Summary page.
